Kimihiko Goto1, Shunsuke Goto1, Hideki Fujii2, Kentaro Watanabe1, Keiji Kono1, Shinichi Nishi1. 1. Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan. 2. Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan. fhideki@med.kobe-u.ac.jp.
Abstract
INTRODUCTION: Recent clinical studies demonstrated the favorable effects of calcium-free phosphate binders on mortality and vascular calcification in hemodialysis (HD) patients. The aim of the present study was to investigate the effects of a calcium-free phosphate binder, lanthanum carbonate (LC), on bone metabolic markers and bone mineral density (BMD), compared with those of calcium carbonate (CC), in subjects new to HD. MATERIALS AND METHODS: The present study included 65 subjects from our previous randomized controlled trial (LC group, N = 31; CC group, N = 34). We investigated the effects of LC on serum intact parathyroid hormone (iPTH), osteocalcin (OC), bone-specific alkaline phosphatase (BAP), tartrate-resistant acid phosphatase 5b (TRACP-5b), sclerostin levels, and BMD, compared with those of CC in patients new to HD at baseline and at 12 and 18 months. RESULTS:Serum OC levels at 18 months were significantly higher in the LC group than in the CC group. During the study period, serum BAP and TRACP-5b and iPTH levels tended to be higher in the LC group than in the CC group. At 18 months, the percentage of low bone turnover, based on a serum BAP cutoff value, was significantly lower in the LC group than in the CC group. There were no significant differences in the lumbar and femoral BMD between the two groups. CONCLUSIONS: The results of the present study suggest that LC has potential in preventing low bone turnover, in comparison to CC, in patients new to HD.
RCT Entities:
INTRODUCTION: Recent clinical studies demonstrated the favorable effects of calcium-free phosphate binders on mortality and vascular calcification in hemodialysis (HD) patients. The aim of the present study was to investigate the effects of a calcium-free phosphate binder, lanthanum carbonate (LC), on bone metabolic markers and bone mineral density (BMD), compared with those of calcium carbonate (CC), in subjects new to HD. MATERIALS AND METHODS: The present study included 65 subjects from our previous randomized controlled trial (LC group, N = 31; CC group, N = 34). We investigated the effects of LC on serum intact parathyroid hormone (iPTH), osteocalcin (OC), bone-specific alkaline phosphatase (BAP), tartrate-resistant acid phosphatase 5b (TRACP-5b), sclerostin levels, and BMD, compared with those of CC in patients new to HD at baseline and at 12 and 18 months. RESULTS: Serum OC levels at 18 months were significantly higher in the LC group than in the CC group. During the study period, serum BAP and TRACP-5b and iPTH levels tended to be higher in the LC group than in the CC group. At 18 months, the percentage of low bone turnover, based on a serum BAP cutoff value, was significantly lower in the LC group than in the CC group. There were no significant differences in the lumbar and femoral BMD between the two groups. CONCLUSIONS: The results of the present study suggest that LC has potential in preventing low bone turnover, in comparison to CC, in patients new to HD.
Entities:
Keywords:
Bone metabolic marker; Initiation of hemodialysis; Lanthanum carbonate; Low bone turnover; Non-calcium-containing phosphate binder
Authors: Sophie A Jamal; Ben Vandermeer; Paolo Raggi; David C Mendelssohn; Trish Chatterley; Marlene Dorgan; Charmaine E Lok; David Fitchett; Ross T Tsuyuki Journal: Lancet Date: 2013-07-19 Impact factor: 79.321
Authors: G Coen; P Ballanti; E Bonucci; S Calabria; M Centorrino; V Fassino; M Manni; D Mantella; S Mazzaferro; I Napoletano; D Sardella; F Taggi Journal: Nephrol Dial Transplant Date: 1998-09 Impact factor: 5.992
Authors: Michael E Seifert; Lisa de las Fuentes; Marcos Rothstein; Dennis J Dietzen; Andrew J Bierhals; Steven C Cheng; Will Ross; David Windus; Víctor G Dávila-Román; Keith A Hruska Journal: Am J Nephrol Date: 2013-08-07 Impact factor: 3.754
Authors: Yunyun Di; Ellen K Wasan; Jacqueline Cawthray; Jaweria Syeda; Munawar Ali; David M L Cooper; Ahmad Al-Dissi; Nima Ashjaee; Wubin Cheng; James Johnston; David M Weekes; Thomas I Kostelnik; Chris Orvig; Kishor M Wasan Journal: Bone Rep Date: 2021-02-11
Authors: Anna Wasilewska; Rose Ann Murray; Aimee Sundberg; Sharif Uddin; Heinrich Achenbach; Aleksey Shavkin; Tamás Szabó; Andrea Vergani; Obi Umeh Journal: BMC Nephrol Date: 2022-03-02 Impact factor: 2.388